• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket

    4/9/24 6:05:24 AM ET
    $ADXN
    $ANGH
    $BCLI
    $BPTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Telecommunications Equipment
    Consumer Discretionary
    Get the next $ADXN alert in real time by email

    Shares of Biophytis S.A. (NASDAQ:BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.

    Biophytis posted a FY23 loss of €0.03 per share, versus a year-ago loss of €0.14 per share, according to data from Benzinga Pro.

    Biophytis shares jumped 55.2% to $0.4920 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) shares rose 40% to $3.64 in pre-market trading after jumping 22% on Monday.
    • MediaCo Holding Inc. (NASDAQ:MDIA) shares rose 20.2% to $3.63 in pre-market trading after falling 22% on Monday. On April 4, an SEC filing showed Standard General L.P. reported a 95.2% stake in the company, as of April 1.
    • Destiny Tech100 Inc. (NASDAQ:DXYZ) gained 18.5% to $118.33 in pre-market trading after jumping over 68% on Monday.
    • Addex Therapeutics Ltd (NASDAQ:ADXN) shares gained 17.2% to $25.60 in pre-market trading after jumping around 21% on Monday. Addex Therapeutics and funds affiliated with Perceptive Advisors, last week, announced the launch of Neurosterix.
    • Anghami Inc. (NASDAQ:ANGH) gained 16.1% to $1.30 in pre-market trading after dipping over 3% on Monday.
    • Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) climbed 15% to $0.8395 in pre-market trading after jumping around 12% on Monday. The company, last week, reported FY23 financial results.
    • Soligenix, Inc. (NASDAQ:SNGX) shares gained 12.5% to $0.54 in pre-market trading after adding around 3% on Monday.
    • TuanChe Limited (NASDAQ:TC) rose 10.8% to $2.16 in pre-market trading.
    • Halozyme Therapeutics, Inc. (NASDAQ:HALO) gained 10.7% to $2.16 in pre-market trading after declining around 3% on Monday.


    Losers

    • Vincerx Pharma, Inc. (NASDAQ:VINC) declined 52.1% to $2.29 in pre-market trading after the company presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the AACR Annual Meeting 2024.
    • Focus Universal Inc. (NASDAQ:FCUV) fell 30.8% to $0.2424 in pre-market trading. Focus Universal, on Monday, announced Warren Wang as Chief Strategy Officer.
    • UTime Limited (NASDAQ:WTO) fell 26.1% to $0.2216 in pre-market trading. UTime shares jumped 62% on Monday after the company completed a private placement.
    • BioSig Technologies, Inc. (NASDAQ:BSGM) fell 22.8% to $0.9570 in pre-market trading after jumping over 96% on Monday.
    • Guardion Health Sciences, Inc. (NASDAQ:GHSI) shares declined 20.8% to $7.05 in pre-market trading.
    • Maxeon Solar Technologies, Ltd. (NASDAQ:MAXN) fell 16.8% to $2.27 pre-market trading. Maxeon Solar said it sees preliminary fourth-quarter revenue of $229 million versus market estimates of $235.959 million.
    • Hanryu Holdings, Inc. (NASDAQ:HRYU) shares fell 15.8% to $0.24 in pre-market trading after jumping over 31% on Monday.
    • VBI Vaccines Inc. (NASDAQ:VBIV) fell 12.4% to $0.8037 in pre-market trading after jumping around 30% on Monday.
    • Eco Wave Power Global AB (NASDAQ:WAVE) shares fell 11.2% to $3.73 in pre-market trading. Eco Wave. Power global shares jumped 219% on Monday after the company announced that it was selected by an international energy company to conduct wave energy feasibility studies for the U.S. coastline.
    • DigiAsia Corp. (NASDAQ:FAAS) fell 9.9% to $7.00 pre-market trading after surging over 20% on Monday.

     

    Now Read This: Neogen, Maxeon Solar Technologies And 3 Stocks To Watch Heading Into Tuesday

    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $ANGH
    $BCLI
    $BPTS

    CompanyDatePrice TargetRatingAnalyst
    Halozyme Therapeutics Inc.
    $HALO
    12/4/2025$56.00Neutral → Sell
    Goldman
    Halozyme Therapeutics Inc.
    $HALO
    10/14/2025$70.00Underperform → Market Perform
    Leerink Partners
    Halozyme Therapeutics Inc.
    $HALO
    8/6/2025$75.00Equal-Weight → Overweight
    Morgan Stanley
    Halozyme Therapeutics Inc.
    $HALO
    7/10/2025$55.00Neutral
    Goldman
    Halozyme Therapeutics Inc.
    $HALO
    5/14/2025$62.00Overweight → Equal-Weight
    Morgan Stanley
    Halozyme Therapeutics Inc.
    $HALO
    5/13/2025$47.00Market Perform → Underperform
    Leerink Partners
    Eco Wave Power Global AB
    $WAVE
    3/11/2025$15.00Buy
    Maxim Group
    Eco Wave Power Global AB
    $WAVE
    2/3/2025$14.00Buy
    Alliance Global Partners
    More analyst ratings

    $ADXN
    $ANGH
    $BCLI
    $BPTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, CEO AND PRESIDENT Schaber Christopher J bought $20,000 worth of shares (15,132 units at $1.32), increasing direct ownership by 3,993% to 15,511 units (SEC Form 4)

    4 - SOLIGENIX, INC. (0000812796) (Issuer)

    10/3/25 1:18:09 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Giustra Frank bought $734,725 worth of shares (178,205 units at $4.12) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    9/15/25 8:19:20 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CEO and Director Wang Desheng bought $2,280 worth of shares (1,000 units at $2.28) and bought $22,260 worth of shares (10,000 units at $2.23), increasing direct ownership by 0.49% to 2,273,800 units (SEC Form 4)

    4 - FOCUS UNIVERSAL INC. (0001590418) (Issuer)

    8/15/25 6:55:39 PM ET
    $FCUV
    Industrial Machinery/Components
    Industrials

    $ADXN
    $ANGH
    $BCLI
    $BPTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Mills Roger

    3 - Addex Therapeutics Ltd. (0001574232) (Issuer)

    3/25/26 4:03:45 PM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Lawton Vincent Michael

    3 - Addex Therapeutics Ltd. (0001574232) (Issuer)

    3/25/26 4:03:03 PM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Teyssedou Lenaic Nathanael

    3 - Addex Therapeutics Ltd. (0001574232) (Issuer)

    3/25/26 4:02:26 PM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ANGH
    $BCLI
    $BPTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Halozyme Therapeutics downgraded by Goldman with a new price target

    Goldman downgraded Halozyme Therapeutics from Neutral to Sell and set a new price target of $56.00

    12/4/25 8:27:01 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Halozyme Therapeutics from Underperform to Market Perform and set a new price target of $70.00

    10/14/25 1:19:46 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Halozyme Therapeutics from Equal-Weight to Overweight and set a new price target of $75.00

    8/6/25 7:53:02 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $ANGH
    $BCLI
    $BPTS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Halozyme Therapeutics Inc.

    SCHEDULE 13G/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Subject)

    3/27/26 9:33:48 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Token Cat Limited

    S-8 - Token Cat Ltd (0001743340) (Filer)

    3/26/26 5:26:50 PM ET
    $TC
    Real Estate

    SEC Form DEFA14A filed by Halozyme Therapeutics Inc.

    DEFA14A - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)

    3/23/26 4:13:32 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $ANGH
    $BCLI
    $BPTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MediaCo Audio Delivers Strong February Ratings Growth Across Key Markets

    MediaCo Holding Inc. (NASDAQ:MDIA) today announced a strong February performance across its audio portfolio, with audience growth in key dayparts and demos driving momentum in New York, Southern California, Dallas-Fort Worth, and Houston. New York led by HOT 97 and WBLS, with HOT 97 rising to #4 in mornings and #3 in afternoons, and Prime AQH up 41% year over year. WBLS posted 35% afternoon AQH growth among Persons 25-54 and strong weekend gains. Southern California delivered one of MediaCo's strongest books, powered by Que Buena (KBUE) in Los Angeles, which saw double-digit AQH growth and major morning gains, and 96.1 KRQB, which posted standout increases including 200% midday growth a

    3/26/26 9:32:00 AM ET
    $MDIA
    Broadcasting
    Consumer Discretionary

    Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

    PRINCETON, N.J., March 26, 2026 /PRNewswire/ --Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to dusquetide (the active pharmaceutical ingredient in SGX945) for the treatment of Behçet's Disease, following review of the recently published Phase 2a clinical results demonstrating biological efficacy and safety in patients with Be

    3/26/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eco Wave Power Advances Taiwan Expansion as Partner Signs Land Lease for Suao Port Wave Energy Project

    TAIPEI, Taiwan, March 23, 2026 /PRNewswire/ -- Eco Wave Power Global AB (publ) ("Eco Wave Power" or the "Company") (NASDAQ:WAVE), a leading developer of onshore wave energy technology, today announced a key milestone in the development of its wave energy project in Suao Port, Taiwan. The Company's Taiwanese partner, I-Ke International Ocean Energy Co. ("I-Ke"), a subsidiary of Lian Tat Company, informed Eco Wave Power that in December 2025 it signed the land lease agreement with Suao Port for the designated wave energy project site. The agreement provides for a five-year lease t

    3/23/26 8:30:00 AM ET
    $WAVE
    Electric Utilities: Central
    Utilities

    $ADXN
    $ANGH
    $BCLI
    $BPTS
    Financials

    Live finance-specific insights

    View All

    Eco Wave Power Reports Strong Operational Progress and Files 2025 Annual Report on Form 20-F

    Company completes first U.S. wave energy pilot project, submits final report to Shell, records highest energy generation at Israeli project, advances megawatt-scale project in Portugal and supports Taiwan project development, while reducing Q4 operating expenses by 24%Stockholm, Sweden--(Newsfile Corp. - March 12, 2026) - Eco Wave Power Global AB (publ) (NASDAQ:WAVE) ("Eco Wave Power" or the "Company"), a leading onshore wave energy technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the "Annual Report") with the U.S. Securities and Exchange Commission (the "SEC").The Annual Report, which includes the Company's aud

    3/12/26 8:30:00 AM ET
    $WAVE
    Electric Utilities: Central
    Utilities

    HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

    Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billionFull Year 2025 Royalty Revenue Increased 52% YOY to Record $868 millionCompleted Acquisitions of Elektrofi's Hypercon™ Technology and Surf Bio's Hyperconcentration TechnologyReiterating 2026 Financial Guidance Ranges:Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30%Adjusted EBITDA of $1.125 - $1.205 billion, YOY Growth of 71% - 83%1Non-GAAP Diluted EPS of $7.75 - $8.25, YOY Growth of 87% - 99%1SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 

    2/17/26 4:01:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

    SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, following the close of trading. Halozyme will host a conference call on Tuesday, February 17, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/624893800?pwd=q3lpEa6F A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a bioph

    2/10/26 4:05:00 PM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $ANGH
    $BCLI
    $BPTS
    Leadership Updates

    Live Leadership Updates

    View All

    MediaCo Appoints Armando Diaz as Vice President, Operations & Efficiency

    MediaCo Holding Inc. (NASDAQ:MDIA) today announced the appointment of Armando Diaz as Vice President, Operations & Efficiency. Diaz will report to Brian Fisher, Chief Revenue Officer of MediaCo. In this role, Diaz will focus on strengthening operational discipline across the organization, simplifying internal processes, and driving sustainable expansion in support of the company's EBITDA growth strategy. Diaz brings more than 20 years of corporate leadership experience, including senior roles within media and broadcast organizations where he has led complex operational environments and cross-functional teams. Throughout his career, he has driven efficiency and transformation initiatives

    3/16/26 8:00:00 AM ET
    $MDIA
    Broadcasting
    Consumer Discretionary

    MediaCo Appoints Neida Gotay as Vice President, Integrated Sales

    MediaCo Holding Inc. (NASDAQ:MDIA) today announced the appointment of Neida Gotay as Vice President, Integrated Sales. In this role, Gotay will oversee both local and national sales operations in Orlando and Atlanta, while also leading strategic business development efforts across all Florida markets. She will focus on driving integrated, multi-platform revenue growth, strengthening agency and client partnerships, and ensuring local market execution aligns with MediaCo's expanding national opportunity. Gotay brings deep experience in media sales leadership and revenue strategy, including 18 years at Hearst Television where she played a key role in building and expanding its network of S

    3/13/26 9:00:00 AM ET
    $MDIA
    Broadcasting
    Consumer Discretionary

    Halozyme Appoints David Ramsay as Interim Chief Financial Officer

    SAN DIEGO, March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer (CFO), effective March 23, 2026. Mr. Ramsay will oversee all financial operations while the company continues its active search for a permanent CFO.Mr. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale‑up. He previously served as Halozyme's Chief Financial Officer from 2003 to 2009 and again from 2013 to 2015, during w

    3/12/26 8:30:00 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADXN
    $ANGH
    $BCLI
    $BPTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Maxeon Solar Technologies Ltd.

    SC 13D/A - Maxeon Solar Technologies, Ltd. (0001796898) (Subject)

    11/26/24 8:54:35 PM ET
    $MAXN
    Semiconductors
    Technology

    Amendment: SEC Form SC 13D/A filed by Anghami Inc.

    SC 13D/A - Anghami Inc (0001871983) (Subject)

    11/19/24 4:15:31 PM ET
    $ANGH
    Telecommunications Equipment
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

    SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

    11/14/24 3:58:00 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care